Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices
(eBook)

Book Cover
Your Rating: 0 stars
Star rating for

Contributors:
Published:
[United States] : Wiley, 2022.
Format:
eBook
Content Description:
1 online resource
Status:

Description

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered, and questions explored within the work include: - Fiscal consequences of curing hepatitis C - mRNA vaccines and the race for a cure - Why the government does not deserve a piece of Biopharma's profits - Paying for drugs whose ultimate value is unknown - The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Also in This Series

More Like This

More Details

Language:
English
ISBN:
9781119881353, 1119881358

Notes

Restrictions on Access
Instant title available through hoopla.
Description
High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered, and questions explored within the work include: - Fiscal consequences of curing hepatitis C - mRNA vaccines and the race for a cure - Why the government does not deserve a piece of Biopharma's profits - Paying for drugs whose ultimate value is unknown - The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
System Details
Mode of access: World Wide Web.

Reviews from GoodReads

Loading GoodReads Reviews.

Citations

APA Citation (style guide)

Lamattina, J. L. (2022). Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley.

Chicago / Turabian - Author Date Citation (style guide)

Lamattina, John L.. 2022. Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley.

Chicago / Turabian - Humanities Citation (style guide)

Lamattina, John L., Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley, 2022.

MLA Citation (style guide)

Lamattina, John L.. Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley, 2022.

Note! Citation formats are based on standards as of July 2022. Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy.

Staff View

Grouped Work ID:
e91e4fa2-608c-206b-07f5-76398721180e
Go To Grouped Work

Hoopla Extract Information

Extract Information was matched by id in access url instead of record id.
hooplaId15161483
titlePharma and Profits
languageENGLISH
kindEBOOK
series
season
publisherWiley
price0.99
active1
pa
profanity
children
demo
duration
rating
abridged
fiction
purchaseModelINSTANT
dateLastUpdatedMay 06, 2025 06:43:57 PM

Record Information

Last File Modification TimeJun 03, 2025 10:37:08 PM
Last Grouped Work Modification TimeJun 03, 2025 10:22:36 PM

MARC Record

LEADER02876nam a22004575i 4500
001MWT18107126
003MWT
00520250505041750.0
006m     o  d        
007cr cn|||||||||
008250505s2022    xxu    eo     000 0 eng d
020 |a 9781119881353 |q (electronic bk.)
020 |a 1119881358 |q (electronic bk.)
02842 |a MWT18107126
029 |a https://d2snwnmzyr8jue.cloudfront.net/jws_9781119881353_180.jpeg
037 |a 18107126 |b Midwest Tape, LLC |n http://www.midwesttapes.com
040 |a Midwest |e rda
099 |a eBook hoopla
1001 |a Lamattina, John L., |e author.
24510 |a Pharma and Profits : |b Balancing Innovation, Medicine, and Drug Prices |h [electronic resource] / |c John L. Lamattina.
2641 |a [United States] : |b Wiley, |c 2022.
2642 |b Made available through hoopla
300 |a 1 online resource
336 |a text |b txt |2 rdacontent
337 |a computer |b c |2 rdamedia
338 |a online resource |b cr |2 rdacarrier
347 |a text file |2 rda
506 |a Instant title available through hoopla.
520 |a High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered, and questions explored within the work include: - Fiscal consequences of curing hepatitis C - mRNA vaccines and the race for a cure - Why the government does not deserve a piece of Biopharma's profits - Paying for drugs whose ultimate value is unknown - The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
538 |a Mode of access: World Wide Web.
6500 |a Business.
6500 |a Chemistry.
6500 |a Industries.
6500 |a Medicine.
6500 |a Pharmaceutical biotechnology.
6500 |a Pharmacology.
6500 |a Science.
6500 |a Electronic books.
7102 |a hoopla digital.
85640 |u https://www.hoopladigital.com/title/15161483?utm_source=MARC&Lid=hh4435 |z Instantly available on hoopla.
85642 |z Cover image |u https://d2snwnmzyr8jue.cloudfront.net/jws_9781119881353_180.jpeg